Use of its NuQ blood tests alongside traditional colorectal cancer screens can reduce the number of colonoscopies by a quarter, according to VolitionRx Limited (NYSE MKT:VNRX).
Presenting to the European Society for Medical Oncology Congress (ESMO), Volition Rx said a combination of an NuQ to test for colorectal cancer (CRC) combined with the conventional faecal immunochemical screening test registered almost a 97% detection for colorectal cancer.
Marielle Herzog, Volition’s lead nucleosomic scientist, said: “False positives add to an already long waiting list and delays diagnosis for patients who have cancer and need swift treatment.
“By undertaking this simple, cost effective blood test in people with a positive faecal test, we can help prevent unneeded referrals for colonoscopy with a small reduction in cancer detection and potentially reduce the colonoscopy waiting time for those at high risk of cancer.”
Using NuQ with a faecal test can also increase screening subject throughput by a third.
Volition plans initially to focus the launch in large European Union countries.
It expects to receive CE Marking for this test later this year and to market the CRC test throughout Europe in 2017.
Story by ProactiveInvestors